{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-076458","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2025-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.078216+00:00","generated_at":"2026-05-20T18:45:16.762369+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Candel's CAN-2409 Phase 3 meets primary endpoint (p=0.0155) in localized prostate cancer; ASCO presentation June 3","bullets":["Statistically significant improvement in DFS (p=0.0155) with 30% risk reduction (HR 0.7) for CAN-2409 plus radiotherapy vs placebo plus radiotherapy.","Secondary endpoints met: 80.4% pathological complete response at two-year biopsy vs 63.6% control (p=0.0015); higher PSA nadir <0.2 ng/ml (67.1% vs 58.6%, p=0.0164).","CAN-2409 well tolerated; treatment-related serious adverse events low (1.7% drug arm vs 2.2% control).","Company plans to submit Biologics License Application for CAN-2409 in Q4 2026.","Data to be presented at ASCO 2025 oral abstract session on June 3, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-076458","json":"https://secwatch.observer/filing/0000950170-25-076458.json","markdown":"https://secwatch.observer/filing/0000950170-25-076458.md","text":"https://secwatch.observer/filing/0000950170-25-076458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025076458/0000950170-25-076458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025076458/cadl-20250522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T18:45:16.762369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}